What is GLP-3R?

What is GLP-3R?

GLP-3R is a synthetic investigational peptide developed as a multi-pathway agonist. It is currently being studied for its potential effects on receptor-mediated signaling, molecular dynamics, and endocrine function in preclinical research models. By activating multiple target receptor subtypes, GLP-3R demonstrates broad systemic effects under investigation for their relevance in endocrine and pathway-level research.Jastreboff A.M. et al. (2023).

Chemical Profile

Published Research Findings

The following findings are summarized from peer-reviewed literature cited in the References section below.

GLP-3R has been examined in endocrine and systemic models, with studies highlighting its influence on receptor binding kinetics, downstream signaling cascades, lipid pathway dynamics, and integrated endocrine pathways. Research also points to its role in multi-system signaling and pathway characterization in preclinical and laboratory settings.

Key Areas Identified in the Literature:

Triple Hormone Receptor Agonism: A New Class of Research Peptides

GLP-3R is studied as a triple-hormone receptor agonist — a class of peptide research compounds that simultaneously target three incretin and metabolic hormone receptors: the GLP-1 receptor, the GIP receptor (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This triple-agonist pharmacological profile represents a significant expansion from earlier dual-agonist compounds. The scientific rationale is that GLP-1 and GIP receptors have complementary and partially synergistic effects on insulin secretion and body weight regulation, while glucagon receptor activation drives hepatic glucose production, fatty acid oxidation, and energy expenditure. Targeting all three simultaneously in research models allows investigation of integrated metabolic regulation across pancreatic, hepatic, adipose, and central nervous system pathways. (Source: Coskun T. et al., 2022; Jastreboff A.M. et al., 2023)

Published Research on Triple Agonist Compounds

A 2023 randomized controlled trial published in the New England Journal of Medicine by Jastreboff et al. investigated a triple GLP-1/GIP/glucagon receptor agonist in participants with obesity across a 48-week treatment period. The trial reported substantial body weight reductions across dose groups, with the highest dose cohort achieving mean weight reductions of approximately 24% from baseline — among the largest reductions reported for any pharmacological intervention in obesity research to date. The study also documented improvements in metabolic markers including blood pressure, lipid profiles, and glycemic control. These findings from triple-agonist compound research represent the leading edge of incretin biology investigation and illustrate the research value of compounds targeting multiple hormone receptor pathways simultaneously. For research purposes only. (Source: Jastreboff A.M. et al., 2023)

References

All research findings on this page are derived from the following peer-reviewed publications. Peptide Royalty makes no independent claims — all statements are attributable to the cited authors and their respective studies.